REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway

[1]  R. Moses,et al.  REGγ Controls Hippo Signaling and Reciprocal NF-κB–YAP Regulation to Promote Colon Cancer , 2018, Clinical Cancer Research.

[2]  Chen Ding,et al.  Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7 , 2017, Nature Communications.

[3]  Lin Liu,et al.  Wild-Type P53 Induces Sodium/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer , 2017, Cellular Physiology and Biochemistry.

[4]  Chen Ding,et al.  Smad7 enables STAT3 activation and promotes pluripotency independent of TGF-β signaling , 2017, Proceedings of the National Academy of Sciences.

[5]  A. Miyauchi,et al.  The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study. , 2016, Thyroid : official journal of the American Thyroid Association.

[6]  V. Syed,et al.  TGF‐β Signaling in Cancer , 2016, Journal of cellular biochemistry.

[7]  Xiaoli Liu,et al.  Targeting TGF-β1 inhibits invasion of anaplastic thyroid carcinoma cell through SMAD2-dependent S100A4-MMP-2/9 signalling. , 2016, American journal of translational research.

[8]  A. Hoffmann,et al.  The REGγ-proteasome forms a regulatory circuit with IκBɛ and NFκB in experimental colitis , 2016, Nature Communications.

[9]  Xin-Hua Feng,et al.  Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling* , 2015, The Journal of Biological Chemistry.

[10]  M. Shen,et al.  Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. , 2015, Endocrine-related cancer.

[11]  R. Moses,et al.  REGγ is critical for skin carcinogenesis by modulating the Wnt/β-catenin pathway , 2015, Nature Communications.

[12]  P. Papageorgis.  TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis , 2015, Journal of oncology.

[13]  Jianqiang Mao,et al.  ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis , 2015, Cell reports.

[14]  H. Reddi,et al.  Anaplastic thyroid cancer – an overview of genetic variations and treatment modalities , 2015 .

[15]  T. Prolla,et al.  Novel approaches in anaplastic thyroid cancer therapy. , 2014, The oncologist.

[16]  R. Latif,et al.  Stemness is Derived from Thyroid Cancer Cells , 2014, Front. Endocrinol..

[17]  D. Hommes,et al.  Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. , 2014, Gastroenterology.

[18]  C. Creighton,et al.  PKA turnover by the REGγ-proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis. , 2014, Journal of molecular and cellular cardiology.

[19]  D. Edwards,et al.  The REGγ proteasome regulates hepatic lipid metabolism through inhibition of autophagy. , 2013, Cell metabolism.

[20]  L. Donehower,et al.  REGγ deficiency promotes premature aging via the casein kinase 1 pathway , 2013, Proceedings of the National Academy of Sciences.

[21]  C. Chi,et al.  HDAC inhibitor induces re-expression of thyroid specific genes as well as differentiating in anaplastic thyroid cancer , 2013 .

[22]  R. Jesenofsky,et al.  Antitumor Effects of Proteasome Inhibition in Anaplastic Thyroid Carcinoma , 2012, The Journal of Nuclear Medicine.

[23]  M. Dewaele,et al.  mRNA Expression in Papillary and Anaplastic Thyroid Carcinoma: Molecular Anatomy of a Killing Switch , 2012, PloS one.

[24]  S. Ševčíková,et al.  TGF-β – an excellent servant but a bad master , 2012, Journal of Translational Medicine.

[25]  Tieliu Shi,et al.  REGγ is associated with multiple oncogenic pathways in human cancers , 2012, BMC Cancer.

[26]  Jin-Rong Zhou,et al.  Smad4 inactivation promotes malignancy and drug resistance of colon cancer. , 2011, Cancer research.

[27]  Shanlou Qiao,et al.  REGγ modulates p53 activity by regulating its cellular localization , 2010, Journal of Cell Science.

[28]  F. He,et al.  REGγ proteasome mediates degradation of the ubiquitin ligase Smurf1 , 2010, FEBS letters.

[29]  P. Santisteban,et al.  The BRAF V600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer , 2009 .

[30]  T. Veenstra,et al.  A Negative Feedback Control of Transforming Growth Factor-β Signaling by Glycogen Synthase Kinase 3-mediated Smad3 Linker Phosphorylation at Ser-204* , 2009, The Journal of Biological Chemistry.

[31]  Ruiwen Zhang,et al.  Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation , 2008, The EMBO journal.

[32]  B. O’Malley,et al.  Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. , 2007, Molecular cell.

[33]  A. Malovannaya,et al.  The SRC-3/AIB1 Coactivator Is Degraded in a Ubiquitin- and ATP-Independent Manner by the REGγ Proteasome , 2006, Cell.

[34]  H. Boezen,et al.  Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. , 2005, Endocrine-related cancer.

[35]  P. Santisteban,et al.  The Functional Interaction between the Paired Domain Transcription Factor Pax8 and Smad3 Is Involved in Transforming Growth Factor-β Repression of the Sodium/Iodide Symporter Gene* , 2004, Journal of Biological Chemistry.

[36]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[37]  I. Hisatome,et al.  Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. , 2003, The Journal of clinical endocrinology and metabolism.

[38]  P. Opolon,et al.  Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. , 2000, Cancer research.

[39]  Jianhui Zhuang,et al.  Galunisertib , a TGF-β receptor ( TβR )-I inhibitor , suppresses growth and invasion of an anaplastic thyroid cancer 8505 C cell in vitro and in vivo , 2016 .